This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Many Philippine companies expand overseas to reach more consumers and increase revenues. Also, companies can utilize global markets to introduce unique products and services (https://www.bizjournals.com/).
SMCP1 UNITDSPR JBFCY PDMXY UVRBY RI SMGBY SMGBF 532432 SMC2B SMC2A JBFCF SMC SMC2D SMC2C SMC2F JFC DMPLF URC SMC2E UQNTY DMPL D03 UVRBF
TEN Philippine companies made it to the Nikkei Asian Review’s third annual list of Asia300 Power Performers Ranking, which ranks the most powerful and valuable listed companies in Asia.
JGSMY GTCAP GTCXY JGS CEBUY JBFCF MPCFF SPHXF SPHZF CEB JGSHF UVRBF AYAAF DMC MPCIY AYAAY JBFCY DMCIF UVRBY DMCP SMPH CEBUF MPI SPHXY JFC URC DMCHY ALI
(July 4): Most Southeast Asian stock markets fell on Wednesday, tracking Asian peers on caution ahead of the Friday deadline for further U.S. tariffs on China, with Philippine shares snapping a three-session gaining streak on profit-taking.
SMIVY JBFCF SVTMF JFC JBFCY SM
SINGAPORE, July 4 — Most South-east Asian stock markets fell today tracking Asian peers on caution ahead of the Friday deadline for further US tariffs on China, with Philippine shares snapping a three-session gaining streak on profit-taking.
SMIVY JBFCF SVTMF JFC JBFCY SM
THE Labor department said it expects more workers to be given regular status soon after it inspects companies it earlier warned about employment practices that amount to illegal contractualization.
JBFCF CNPF JFC JBFCY
The benchmark Philippine Stock Exchange index (PSEi) continued its descent on Friday, briefly dropping below the 7,000 level before bargain hunters entered the fray.
MER SVTMF PSKXF MPCIY BDOUY AYAAY JBFCY SM BDOUF SMPH BDO SMIVY JBFCF MPI MPCFF SPHXY JFC PHSXY PSE SPHXF SPHZF ALI AYAAF
The benchmark Philippine Stock Exchange index (PSEi) managed to close with a small gain on Wednesday, a day after inflation fears eased with the release of data for May.
GTCAP GTCXY GTMEY BDOUY BDOUF JBFCF PHSXY GTMEF PSE SPHXF SPHZF GLOPA AYAAF PSKXF AYAAY JBFCY GLOPP SMPH BDO GLO SPHXY JFC BBRRF BLOOM ALI LTG
The local stock barometer yesterday sagged for the third trading session as foreign funds continued to flow out of the local bourse while labor woes further dampened sentiment.
SVTMF PSKXF NIKL NOW AYAAY JBFCY SM NIKAY SMIVY JBFCF JFC PHSXY PSE DNOW ALI AYAAF
After netizens pressed the Department of Labor and Employment (DOLE) to explain why certain companies were obviously missing in the list of top 20 labor-only contracting companies, the department said there is an explanation behind it.
JBFCF JFC JBFCY
(Reuters) - Luxembourg-based JAB Holdings is set to buy British sandwich chain Pret A Manger for 1.5 billion pounds ($2.0 billion), including debt, from its private equity owners, the Financial Times reported late on Monday.
JBFCF JFC JBFCY
14h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
15h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...